Secondary treatment of advanced cancer of the prostate with Zoladex.
Twelve patients with advanced prostatic carcinoma and relapse following previous hormone manipulation therapy were treated with Zoladex-depot every 4 weeks. The treatment was well tolerated and the endocrine response was satisfactory. However, no clinically important improvement was obtained.
Klarskov
P
P
Department of Urology, Herlev Hospital, Denmark.
Lund
F
F
Petersen
S E
SE
D000368:Aged; D000369:Aged, 80 and over; D002064:Buserelin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D017273:Goserelin; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012074:Remission Induction
D003692:Delayed-Action Preparations; D017273:Goserelin; D002064:Buserelin